About Dr. Holub

Education | Professional Training | Academic Appointment | Professional Certifications | Research Studies

WMHT NeuroAssocAlb_1

Dr. Richard Holub is president of Neurological Associates of Albany, PC (NAA) an organization that consists of a highly respected clinic providing a full complement of neurological services and a well established research center. The clinical arm of NAA currently has a panel of over 2,000 patients and provides comprehensive neurological services to over 1,000 patients diagnosed with Alzheimer's disease, MCI, or other forms of dementia.

In addition to providing high quality neurological care, Dr. Holub is also the principal investigator for the Research Division of NAA, where he has been conducting phase II and Phase III clinical trials for over 30 years. During his impressive career, Dr. Holub has conducted over 125 successful clinical trials and has played a significant role in the investigation of all five drugs currently approved by the FDA for the Treatment of Alzheimer's Disease, he has also been involved in clinical trials investigation treatments for Major Depression, Generalized Anxiety Disorder, Multiple Sclerosis, and painful Diabetic Neuropathy among others.

NAA's Research Division encompasses over 3,000 square feet of space and houses three experienced research coordinators, two psychomatricians, a physician's assistant as well as lab and support personnel. The office has a fully functioning lab, a two-chair infusion suite, three exam rooms and two testing rooms. NAA also has long standing professional relationships with a number of local imaging centers which allows it to conduct all of the activities that are a typical part of any standard clinical trial.

Since NAA staff prescreens every patient, the division's screen failure rate is very low. NAA is noted for our ability to recruit high numbers of eligible patients and associated high retention rates.

Education

Rutgers University - Degree: BA in Biology 1965-1969
Georgetown University School of Medicine - Degree: M.D. 1969-1973

Professional Training

Internship - Internal Medicine
Albany Medical Center Hospital
1973-1974
Neurological Residency
Albany Medical Center Hospital
1974-1977

Academic Appointment

Clinical Assistant Neurologist

Department of Neurology at Albany Medical College

1977-present

Professional Certifications

NYS License #120621-1 1974
Diplomat, American Board of Psychiatry and Neurology 1978

Research Studies

The following is a list of some, but not all of the research conducted by Dr. Holub's Research Division.

"Cell Mediated Immunity in Multiple Sclerosis" 1980-1985
Clinical Trial of "Suloctidil" for the treatment of Alzheimer’s Disease 1985-1988
Clinical Trial of "HP029" in the treatment of Alzheimer's Disease 201/202/303 1988-1994
Clinical Trial of "Trental" for the treatment of Multi-Infarct Dementia 1990-1993
Clinical Trial of "Besipirdine" for the treatment of Alzheimer's Disease 1993-1994
Clinical Trial of "Sabeluzole" for the treatment of Alzheimer's Disease
STUDY PROTOCOL: Double Blind
1994-1995
Clinical Trial of "CI-979" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Phase II

1994-1996
Clinical Trial of "Physostigmine" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Double Blind 1025

1995-1996
Clinical Trial of "CI-979" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Phase III

1995-1997
Clinical Trial of "Physostigmine" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Open Label 1025B

1996-1996
Clinical Trial of "CI-970-68" for the treatment of Alzheimer's Disease 1996-1999
Clinical Trial of "E2020-A001-312" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Phase IIIB

1996-1998
Clinical Study of SPECT Imaging in probable Alzheimer’s Disease patients. 1996-1996
Clinical Trial of "E2020-A001-314" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Open Label

1997-1998
Clinical Trial of "E2020-A001-307" in Patients with Dementia associated with Cerebrovascular Disease

STUDY PROTOCOL: Double Blind 1997-2001

1997-2001
Clinical Trial of "E2020-A001-309" in patients with Dementia associated with Cerebrovascular Disease

STUDY PROTOCOL: Open Label

1998-2001
Clinical Trial of "Galantamine" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Phase III

1996-1998
Clinical Trial of "Galantamine" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Open Label

1997-2001
Clinical Trial of "Lazabemide" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Phase III, Double Blind

1997-1998
Clinical Trial of "Lazabemide" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Open Label

1998-1999
Clinical Trial of "Metrifonate" for the treatment of Alzheimer's Disease

STUDY PROTOCOL: Phase III

1997-1998
Clinical Trial of "Idebenone" for the Treatment Of Alzheimer's Disease

STUDY PROTOCOL: Phase III

1997-1999
Clinical Trial of "MK-0966" for the prevention of Alzheimer's Disease 1998-1999
Clinical Trial of "Pregabalin" for the treatment of patients with Post Herpetic Neuralgia Pain

STUDY PROTOCOL: Double Blind

1998-2003
Clinical Trial of "Pregabalin" for the treatment of patients with Diabetic Peripheral Neuropathy Pain

STUDY PROTOCOL: Double Blind

1998-1999
Clinical Trial of “Pregabalin” for the treatment of patients with Post Herpetic Neuralgia Pain

STUDY PROTOCOL: Open Label

1998-2001
Clinical Trial of “Pregabalin” for the treatment of patients with Diabetic Peripheral Neuropathy Pain

STUDY PROTOCOL: Open Label

1998-2001
Clinical Trial of the Safety And Efficacy under a slow titration regimen of "Galantamine" in the treatment of Alzheimer's Disease.

STUDY PROTOCOL: Phase III, Double Blind

1998-1999
Clinical Trial of “Galantamine” during withdrawal in the treatment of Alzheimer’s Disease 1999-1999
Clinical Trial of “Galantamine” in the treatment of Alzheimer’s Disease

STUDY PROTOCOL: Open Label

1999-2001
Clinical Trial of "Olanzapine Vs. Risperidone" and Placebo in the treatment of Psychosis and associated Behavioral Disturbances in patients with Dementia 1998-2001
Clinical Trial of "Ginkgo Biloba Special Extract" in the treatment of patients with Alzheimer's Disease

STUDY PROTOCOL: Double Blind

1998-2000
Clinical Trial of “Donepezil’ in subjects with Mild Cognitive Impairment

STUDY PROTOCOL: Double Blind.

1999-2001
Clinical Trial of “Galantamine” in the treatment of Alzheimer’s Disease Cardiac safety study 1999-1999
Clinical Trial of “Donepezil” in the treatment of Alzheimer’s Disease withdrawal and Re-Challenge 2000-2001
Clinical Trial of “Buspirone Hydrochloride ER” in the treatment of Generalized Anxiety Disorder

STUDY PROTOCOL: Double Blind

1999-2001
Clinical Trial of “Buspirone Hydrochloride ER” in the treatment of Generalized Anxiety Disorder

STUDY PROTOCOL: Open Label.

2001-2002
Clinical Trial of “MKC-242” in the treatment of Major Depressive Disorder 1999-2001
Clinical Trial of “E2020-405” in the treatment of Cognitive Impairment in patients with Multiple Sclerosis 2000-2001
Clinical Trial of “Glatiramer Acetate” orally administered in Relapsing and Remitting Multiple Sclerosis patients. 2000-2001
Clinical Trial of “OPC – 14523” in patients with Moderate Depression 2000-2001
Clinical Trial of “CI-1017” in patients with Mild to Moderate Alzheimer’s Disease 2000-2001
Clinical Trial of “Pregabalin” in elderly patients with Generalized Anxiety Disorder 2000-2001
Clinical Trial of “Aripiprazole” in the treatment of institutionalized patients with Psychosis associated with Dementia of the Alzheimer’s type 2000-2001
Clinical Trial of Controlled Release “Galantamine” in patients with Mild To Moderate Alzheimer’s Disease.

STUDY PROTOCOL: Double Blind

2001-2002
Clinical Trial of “CP-457, 920” In Patients With Mild To Moderate Alzheimer’s Disease.

STUDY PROTOCOL: Double Blind.

2001-2002
Clinical Trial of “Galantamine” in patients with Mild Cognitive Impairment

STUDY PROTOCOL: Double Blind.

2001-2003
Clinical Trial of “FK960” in patients with Mild To Moderate Alzheimer’s Disease.

STUDY PROTOCOL: Double Blind.

2001-2002
Clinical Trial of “Memantine” in patients with Moderate to Severe Dementia of the Alzheimer’s type

STUDY PROTOCOL: Double Blind.

2001-2003
Clinical Trial of “Memantine” in patients on “Donepezil” with Moderate to Severe Alzheimer’s Disease

STUDY PROTOCOL: Double Blind.

2001-2003
Clinical Trial of “Memantine” in patients with Moderate to Severe Alzheimer’s Disease

STUDY PROTOCOL: Long Term Extension

2001-2005
Clinical Trial of Controlled Release “Galantamine” in patients with Mild to Moderate Alzheimer’s Disease.

STUDY PROTOCOL: Open Label

2001-2003
Clinical Trial of “FK960” in patients with Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Open Label

2001-2002
Clinical Trial of “Galantamine” in patients with Dementia secondary to Cerebrovascular Disease

STUDY PROTOCOL: Double Blind

2001-2003
Clinical Trial of “DERA 025” in treatment of patients with Generalized Anxiety Disorder

STUDY PROTOCOL: Double Blind

2001-2002
Clinical Trial of Efficacy and Safety of “Atorvastatin 80 mg” plus Acetyl Cholinesterase Inhibitor vs. Acetyl Cholinesterase Inhibitor Only - 80 Weeks

STUDY PROTOCOL: Double Blind

2004-2007
Clinical Trial of “E2020A001-319” evaluating “Donepezil” in patients with Cerebrovascular Dementia

STUDY PROTOCOL: Double Blind.

2002-2005
Clinical Trial of “Galantamine” in patients with Mild Cognitive Impairment.

STUDY PROTOCOL: Open Label

2003-2005
Clinical Trial of “Donepezil” in treatment of patients with Moderate to Severe Alzheimer’s Disease 2002-2005
Clinical Trial of “MKC- 231” in treatment of patients with Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Double Blind

2002-2005
Clinical Trial of “Neramexane” in treatment of Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Double Blind

2003-2005
Clinical Trial of “Neramexane” in treatment of Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Open Label.

2003-2005
Clinical Trial of “MKC-231” in treatment of Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Open Label

2003-2005
Clinical Trial of three doses of “NS2330” in treatment of patients with Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Double Blind.

2003-2005
Clinical Trial of “Bupropion Hydrochloride” in prevention of Seasonal Affective Disorder

STUDY PROTOCOL: Double Blind

2003-2005
Clinical Trial of “L-830982” in treatment of patients with Generalized Anxiety Disorder

STUDY PROTOCOL: Double Blind.

2002-2003
Clinical Trial of “Donepezil” in treatment of patients with Mild Cognitive Impairment

STUDY PROTOCOL: Double Blind

2003-2006
Clinical Trial of “Avonex” Versus “Betaseron” in the treatment of patients with Relapsing and Remitting Multiple Sclerosis 2003-2005
Four-Week, Non-Intervention Study to assess the validity of various Assessment Scales measuring Cognitive and Executive Function, Attention, Behavior and Activities of Daily Living in patients with Mild to Moderate Parkinson Disease 2003-2005
Clinical Trial of “MK-0677” in slowing the progression of Alzheimer’s Disease

STUDY PROTOCOL: Double Blind

2003-2006
Clinical Trial of Efficacy of “Donepezil Hydrochloride (E2020)” in patients with Mild Cognitive Impairment

STUDY PROTOCOL: Double blind

2003-2007
Clinical Trial of “Xaliproden” in patients with Mild to Moderate Alzheimer’s Disease 2003-2007
Clinical Trial Dose Ranging Study of “SB-683699” to investigate MRI Efficacy And Safety in treatment of patients with Relapsing Multiple Sclerosis 2004-2005
Clinical Trial investigating safety and efficacy of “Neramexane” in patients with Severe Alzheimer’s Disease 2004-2005
Follow-Up Study with patients previously enrolled in MKC231/01, MKC231/02, MKC231/03 or MKC231/04 2004-2005
Clinical Trial of the safety and tolerability of Four Dosing “Memantine” in patients with Moderate to Severe Alzheimer’s Disease 2004-2005
Clinical Trial of efficacy, safety and tolerability of “Donepezil Hydrochloride (E2020)” in treatment of patients with Dementia associated with Cerebrovascular Disease 2004-2005
Clinical Trial of Long-Term Safety and Tolerability of “Galantamine HBR” in the treatment of Mild Cognitive Impairment

STUDY PROTOCOL: Open Label

2004-2005
Clinical Trail of “FK962” in patients with Mild To Moderate Alzheimer’s Disease

STUDY PROTOCOL: Phase II, Double Blind

2004-2006
Clinical Trail of Safety And Efficacy of “ONO-2506PO” in patients with Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Phase II, Double Blind

2004-2006
Clinical Trial of the Efficacy and Safety Of “Alzhemed” TM in Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Phase III

2004-2006
An Analysis of Mortality in subjects with Mild Cognitive Impairment who participated in three studies of “Galantamine” 2004-2005
Clinical Trial comparing the efficacy of “Betaseron” 250 mcg subcutaneously every other day with “Avonex” 30 mcg intramuscularly once weekly in Relapsing-Remitting Multiple Sclerosis Patients 2004-2005
Clinical Trial investigating the safety, tolerability and efficacy of “Betaseron” in Relapsing-Remitting Multiple Sclerosis Patients 2005-2006
Clinical Trial of “Donepezil Hydrochloride (E2020)” in treatment of patients with severe Alzheimer’s Disease

STUDY PROTOCOL: Double Blind

2005-2005
Clinical Trial of “Donepezil Hydrochloride (E2020)” in treatment of patients with severe Alzheimer’s Disease

STUDY PROTOCOL: Open Label

2005-2005
Clinical Trial of “Donepezil Hydrochloride (E2020)” in treatment of patients with Mild Cognitive Impairment

STUDY PROTOCOL: Open Label

2006-2007
Clinical Trial of the efficacy and safety of “Alzhemed” TM in Mild to Moderate Alzheimer’s Disease

STUDY PROTOCOL: Open Label

2006-2008
Clinical Trial of the safety, efficacy and tolerability of 3 doses of “Lecozotan (SRA-333)” in patients with Mild to Moderate Alzheimer’s Disease 2006-2007
Clinical Trial of the safety, efficacy and tolerability of 3 Doses of “Lecozotan (SRA-333)” and Cholinesterase Inhibitor in patients with Mild to Moderate Alzheimer’s Disease 2006-2007
Clinical Trial of long-term efficacy of “Lecozotan (SRA-333)” in patients with Mild to Moderate Alzheimer’s Disease 2007-2008
Clinical Trial of The long-term efficacy of “Lecozotan (SRA-333)” and Cholinesterase Inhibitor in patients with Mild to Moderate Alzheimer’s Disease 2006-2008
Observational Study on costs and Caregiver Burden in Alzheimer’s Disease 2007-2008
Clinical trial to evaluate the effectiveness and safety of “ Donepezil Hydrochloride (E2020)” in subjects with Mild to Severe Alzheimer’s Disease residing in an Assisted Living Facility.

STUDY PROTOCOL: Open Label

2007-2010
Clinical trial of the efficacy and safety of “Bapineuzumab” in patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein Eε4 non-carriers.

STUDY PROTOCOL: Double Blind

2007-2012
Clinical Trial of the efficacy and safety of “Bapineuzumab” in patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein Eε4 carriers.

STUDY PROTOCOL: Double Blind

2007-2012
Clinical trial of the safety and efficacy of oral “ELND005 (AZD-103)” in Alzheimer’s Disease.

STUDY PROTOCOL: Double Blind

2007-2009
Clinical Trial evaluating the safety and efficacy of “CG5503 Extended Release (ER)” in subjects with painful Diabetic Peripheral Neuropathy 2007-2009
Clinical Trial comparing the combined use of “Interferon Beta-la” and ”Glatiramer Acetate” to either agent alone in patients with Relapsing Remitting Multiple Sclerosis.

STUDY PROTOCOL: Double Blind.

2007-2009
Clinical Trial to examine the safety and efficacy of “ACP-103” in the treatment of Psychosis in Parkinson’s Disease.

STUDY PROTOCOL: Double Blind

2008-2009
Clinical Study to evaluate the safety and imaging characteristics of “18F-AV-45” in healthy volunteers, patients with Mild Cognitive Impairment, and patients with Alzheimer’s Disease.

STUDY PROTOCOL: Open Label

2008-2010
Clinical Study to evaluate the comparative efficacy, safety, and tolerability of “Exelon10 and 15 cm2 Patch” in patients with Alzheimer’s Disease showing decline during an initial Open-Label treatment phase.

STUDY PROTOCOL: Double Blind

2008-2011
Clinical Trial comparison of “23 mg Donepezil Sustained Release” to “10 mg Donepezil Immediate release” in patients with Moderate to Severe Alzheimer’s Disease.

STUDY PROTOCOL: Double Blind

2008-2011
Clinical Trial to evaluate the effect of regularly scheduled neutralizing antibody testing on treatment patterns versus usual care in “High Dose Interferon” treated subjects.

STUDY PROTOCOL: Open Label

2008-2010
Clinical Trial to investigate the efficacy and safety of “T-817MAa” in patients with Mild to Moderate Alzheimer’s Disease.

STUDY PROTOCOL: Double Blind

2008-2010
An extension study of “23 mg Donepezil Sustained Release” in patients with Moderate to Severe Alzheimer’s Disease

STUDY PROTOCOL: Open Label Extension

2008-2010
A 26-Week, Multicenter, randomized, placebo-controlled, parallel group study to evaluate the efficacy and safety of “PRX-03140” in subjects with Alzheimer’s Disease receiving a stable dose of “Donepezil”

STUDY PROTOCOL: Phase II, Double Blind

2009-2011
A 26 week, multicenter, randomized, placebo controlled, parallel group study to evaluate the efficacy and safety of “PRX-03140” as monotherapy in subjects with Alzheimer’s Disease.

STUDY PROTOCOL: Phase II, Double Blind

2009-2011
A study of the correlation between “Florpiramine F 18” (18F-AV-45) PET Imaging and Amyloid Pathology

STUDY PROTOCOL: Phase III

2009-2012
PrecisionMed-Sample Registry: Serial Alzheimer’s Disease and MCI Prospective Longitudinal Evaluation.
Longitudinal cognition follow-up and serial DNA/RNA/SERUM/PLAZMA/CFS Banking in subjects with MCI or Mild Alzheimer’s Disease
2009-2012
A multicenter, randomized, placebo-controlled, parallel group, Efficacy and Safety Trial of “Bapineuzumab” (AAB-001, ELN115727) in patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E ε4 Carriers

STUDY PROTOCOL: Phase III, Double Blind

2009-2012
A Long-Term Follow-Up Study of oral “ELND005 (AZD-103)” in subjects with Alzheimer’s disease 2009-2012
A multicenter study evaluating patient injection satisfaction with two formulations of “Glatiramer Acetate” (GA) for subcutaneous injection utilizing Autoject2® Devices.

STUDY PROTOCOL: Open Label

2010-2010
Longitudinal study of long-term (36 month) cognitive outcomes in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimer’s disease (AD) who have previously had PET imaging with “Florbetapir F 18” (F-AV-45) Injection. 2010-2011
Autopsy follow-up of subjects previously imaged with “Florbetapir F 18” (18F-AV-45) PET in trial 18F-AV-45- A07 2010-2011
JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with “Tysabri”®: STRATIFY-2 2010-2013
A multicentered extension trial, evaluating the long term safety and tolerability treatment of “Bapineuzumab” (AAB-001 , ELN115727) in subjects with Alzheimer’s Disease who participated in Study ELN115727-301 or in study ELN115727-302

STUDY PROTOCOL: Phase III, Double Blind

2009-2013
An 8-week, randomized, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of “Agomelatine” 0.5 mg and 1 mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD)

STUDY PROTOCOL: Double Blind

2011-2011
Long term, prospective, observational multinational parallel-cohort study monitoring safety in patients with Multiple Sclerosis (MS) newly started with “Fingolimod” once daily or treated with another approved disease modifying therapy. CFTY720D2403

STUDY PROTOCOL: Phase IV, Open Label, Observational

2011-2014
A 12 month, randomized study to compare the efficacy and safety of “Fingolimod” 0.25mg and 0.5mg administered orally with Glatiramer acetate 20mg administered subcutaneously once daily in patients with Relapsing & Remitting Multiple Sclerosis. Novartis CFTY720D2312

STUDY PROTOCOL: Phase IIIb, Rater and Dose Blinded

2012-2014
A 12 month, Prospective, randomized, active controlled study to evaluate the patient retention of “Fingolimod” vs. approved first line DMT in adults who are in early stages of treatment for Relapsing & remitting Multiple Sclerosis. Novartis CFTY720DUS09

STUDY PROTOCOL: Phase IV, Open Label

2012-2014
A phase 2 clinical trial to evaluate the efficacy and safety of AZD4694 PET in the detection of Beta Amyloid in subjects with probable Alzheimer’s Disease, Older Healthy Volunteers and Young Healthy Volunteers. Navidea NAVA-01

STUDY PROTOCOL: Phase II

2012-2014
A randomized, double blind placebo controlled, parallel-group, 15 month trial of Leuco-methylthionium bis (hydromethanesulfonate) in subjects with Mild to Moderate Alzheimer’s Disease. TauRx TRx-237-015

STUDY PROTOCOL: Phase III, Double Blinded

2013-
A randomized, double blind, placebo controlled, parallel-group, 18 month safety and efficacy study of Leuco-methylthionium bis (hydromethanesulfonate) in subjects with Mild Alzheimer’s Disease. TauRx TRx-237-005

STUDY PROTOCOL: Phase III, Double Blinded

2013-
A randomized, double blind placebo controlled, parallel-group, 12 month safety and efficacy trial of Leuco-methylthionium bis (hydromethanesulfonate) in subjects with behavioral variant frontotemporal dementia (bvFTD). TauRx TRx-237-007

STUDY PROTOCOL: Phase III, Double Blinded

2013-
Beta Amyloid Imaging with 18F NAV4694 Positron Emission Tomography (PET) in predicting progression to Alzheimer’s Disease (AD) in subjects with Mild Cognitive Impairment (MCI)

STUDY PROTOCOL: Phase II

2013-